About Us

Publications

BMT CTN investigators have published >135 manuscripts, including >30 primary study results papers, in numerous peer-reviewed journals, including the New England Journal of Medicine, Journal of Clinical Oncology, and Blood. Selected publications are summarized for dissemination to patients and the lay public.

Note: Some Publications were unable to be listed below - please see that listing here. All other publications based on PubMedIDs are listed below.

 

Found 19 results
Filters: Author is Giralt, Sergio  [Clear All Filters]
2022
A. Dispenzieri, Krishnan, A., Arendt, B., Blackwell, B., Wallace, P. K., Dasari, S., Vogl, D. T., Efebera, Y., Fei, M., Geller, N., Giralt, S., Hahn, T., Howard, A., Kohlhagen, M., Landau, H., Hari, P., Pasquini, M. C., Qazilbash, M. H., McCarthy, P., Shah, N., Vesole, D. H., Stadtmauer, E., and Murray, D., Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT)., Blood Cancer J, vol. 12, no. 2, p. 27, 2022.
Q. Bashir, Nishihori, T., Pasquini, M. C., Martens, M. J., Wu, J., Alsina, M., Anasetti, C., Brunstein, C., Dawson, P., Efebera, Y., Gasparetto, C., Geller, N., Giralt, S., Hall, A. C., Koreth, J., McCarthy, P., Scott, E., Stadtmauer, E. A., Vesole, D. H., and Hari, P., A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 Trial., Transplant Cell Ther, 2022.
L. Luznik, Pasquini, M. C., Logan, B., Soiffer, R. J., Wu, J., Devine, S. M., Geller, N., Giralt, S., Heslop, H. E., Horowitz, M. M., Jones, R. J., Litzow, M. R., Mendizabal, A., Muffly, L., Nemecek, E. R., O'Donnell, L., O'Reilly, R. J., Palencia, R., Schetelig, J., Shune, L., Solomon, S. R., Vasu, S., Ho, V. T., and Perales, M. - A., Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies., J Clin Oncol, vol. 40, no. 4, pp. 356-368, 2022.
A. D'Souza, Brazauskas, R., Stadtmauer, E. A., Pasquini, M. C., Hari, P., Bashey, A., Callander, N., Devine, S., Efebera, Y., Ganguly, S., Gasparetto, C., Geller, N., Horowitz, M. M., Koreth, J., Landau, H., Brunstein, C., McCarthy, P., Qazilbash, M. H., Giralt, S., Krishnan, A., and Flynn, K. E., Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma., Am J Hematol, 2022.
2021
L. W. Dillon, Gui, G., Logan, B. R., Fei, M., Ghannam, J., Li, Y., Licon, A., Alyea, E. P., Bashey, A., Devine, S. M., Fernandez, H. F., Giralt, S., Hamadani, M., Howard, A., Maziarz, R. T., Porter, D. L., Warlick, E. D., Pasquini, M. C., Scott, B. L., Horwitz, M. E., H Deeg, J., and Hourigan, C. S., Impact of Conditioning Intensity and Genomics on Relapse After Allogeneic Transplantation for Patients With Myelodysplastic Syndrome., JCO Precis Oncol, vol. 5, 2021.
L. J. Costa, Derman, B. A., Bal, S., Sidana, S., Chhabra, S., Silbermann, R., Ye, J. C., Cook, G., Cornell, R. F., Holstein, S. A., Shi, Q., Omel, J., Callander, N. S., Chng, W. Joo, Hungria, V., Maiolino, A., Stadtmauer, E., Giralt, S., Pasquini, M., Jakubowiak, A. J., Morgan, G. J., Krishnan, A., Jackson, G. H., Mohty, M., Mateos, M. Victoria, Dimopoulos, M. A., Facon, T., Spencer, A., San Miguel, J., Hari, P., Usmani, S. Z., Manier, S., McCarthy, P., Kumar, S., Gay, F., and Paiva, B., International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials., Leukemia, vol. 35, no. 1, pp. 18-30, 2021.
B. L. Scott, Pasquini, M. C., Fei, M., Fraser, R., Wu, J., Devine, S. M., Porter, D. L., Maziarz, R. T., Warlick, E., Fernandez, H. F., Soiffer, R. J., Alyea, E., Hamadani, M., Bashey, A., Giralt, S., Geller, N. L., Leifer, E., Hourigan, C. S., Gui, G., Mendizabal, A., Horowitz, M. M., H Deeg, J., and Horwitz, M. E., Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial., Transplant Cell Ther, vol. 27, no. 6, pp. 483.e1-483.e6, 2021.
2017
A. D'Souza, Pasquini, M., Logan, B., Giralt, S., Krishnan, A., Antin, J., Howard, A., Goodman, S., Qazilbash, M., Knust, K., Sahebi, F., Weisdorf, D., Vesole, D., Stadtmauer, E., Maloney, D., and Hari, P., Heavy/light chain ratio normalization prior to transplant is of independent prognostic significance in multiple myeloma: a BMT CTN 0102 correlative study., Br J Haematol, vol. 178, no. 5, pp. 816-819, 2017.
B. L. Scott, Pasquini, M. C., Logan, B. R., Wu, J., Devine, S. M., Porter, D. L., Maziarz, R. T., Warlick, E. D., Fernandez, H. F., Alyea, E. P., Hamadani, M., Bashey, A., Giralt, S., Geller, N. L., Leifer, E., Le-Rademacher, J., Mendizabal, A. M., Horowitz, M. M., H Deeg, J., and Horwitz, M. E., Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes., J Clin Oncol, vol. 35, no. 11, pp. 1154-1161, 2017.
S. A. Holstein, Jung, S. - H., Richardson, P. G., Hofmeister, C. C., Hurd, D. D., Hassoun, H., Giralt, S., Stadtmauer, E. A., Weisdorf, D. J., Vij, R., Moreb, J. S., Callander, N. S., van Besien, K., Gentile, T. G., Isola, L., Maziarz, R. T., Bashey, A., Landau, H., Martin, T., Qazilbash, M. H., Rodriguez, C., McClune, B., Schlossman, R. L., Smith, S. E., Hars, V., Owzar, K., Jiang, C., Boyd, M., Schultz, C., Wilson, M., Hari, P., Pasquini, M. C., Horowitz, M. M., Shea, T. C., Devine, S. M., Linker, C., Anderson, K. C., and McCarthy, P. L., Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial., Lancet Haematol, vol. 4, no. 9, pp. e431-e442, 2017.